Studies are revealing that lymphoid neoplasms are characterized by well-defined chromosome translocations and by the accumulation of subsequent molecular alterations involving mainly the cell cycle and/or apoptotic pathways. However, survival of B and T tumor cells is also dependent on the interactions with the accompanying cells that comprise the lymphoma microenvironment. Although non-tumor cells can contribute both positive and negative signals to the lymphoma cells, in this review we present compelling evidence of the essential influence of the tumor microenvironment on the initiation and progression of specific lymphoma types, highlighting some new therapeutic approaches that target the lymphoma microenvironment.
Introduction
Tumor genesis and progression are driven by a combination of intrinsic eventsFoncogene activation and tumor-suppressor gene inactivation 1 Fand extrinsic events that are dependent on the interaction with the stroma. Multiple lines of evidence indicate that the lymphoma microenvironment plays an essential role in tumor origin. We will draw particular attention to some specific issues such as the development of lymphomas in sites usually lacking lymphocytes, as is the case for most of the extranodal lymphomas, the conspicuous presence of a complex cellular milieu that infiltrates some tumors, as is the rule in Hodgkin lymphoma (HL), and the case of the diffuse large B-cell lymphoma (DLBCL) variant known as Histiocyte/Tcell-rich Large B-cell Lymphoma (LBCL). Equally important is the demonstration that removing bacteria or viruses from the lymphoma microenvironment may stop lymphoma growth, with comparable effects to those obtained from chemotherapy. [2] [3] [4] However, the role of the tumor microenvironment in initiating events in lymphoma development and tumor progression has not yet been studied in depth. The tumor microenvironment is composed of a dynamic and interactive mixture of cell subpopulations and cytokines, some of which have been only partially explored to date. Here, we review some of the most compelling evidence of a key role of the microenvironment in lymphoma pathogenesis (Table 1) .
Specific cell subpopulation components of the tumor microenvironment
In recent years, a wide repertoire of new immune-cell subpopulations with characteristic cell-surface phenotypes, gene-expression profiles and functions has been recognized. In this section, we will restrict ourselves to those cell subpopulations that are essential to explain the interactions between the tumor and its microenvironment, focusing on T cells, macrophages and dendritic cells ( Table 2) .
Regulatory T cells
Regulatory T (Treg) cells are a specific subset of T cells that have the capacity to inhibit effector immune responses mediated by CD4 and CD8 T cells, in order to restore immune homeostasis after antigen response and to suppress inappropriate immunoreactivity. Treg cells were initially characterized by the surface expression of CD25. However, this marker is also expressed in recently activated T cells, which have no suppressive capacity. Currently, the transcription factor FOXP3, a member of the forkhead family of DNA-binding transcription factors, 42 has been generally accepted as being a definitive marker of Treg cells. 27, 43 Their development can be triggered by low-affinity antigen stimulation and seems to be dependent on cytokine signaling and to be independent of CD28. Treg cells can mediate their effects by producing immunosuppressive cytokines such as interleukin 10 (IL-10) or transforming growth factor-b (TGF-b), or by mechanisms involving direct interactions with responding T cells or antigen-presenting cells. 28 The presence of Treg cells has been shown to be associated with different clinical outcomes, depending on their location, number and tumor context. Whereas they are associated with the induction of tumor tolerance in epithelial tumors, high numbers of Treg cells are a favorable trait in HL and follicular lymphoma (FL). 9, 14 Follicular B-helper T cells Follicular B-helper T (T FH ) cells represent a heterogeneous population that differs from all other T-cell populations. It can be further divided into several subpopulations on the basis of the expression of different surface markers such as CD25, CD57, CD69 and CXCR5. It is still unclear whether T FH cells differentiate as a third, separate lineage at the time of T-cell priming, or whether they emerge at a later stage from nonpolarized, primed T cells, or even from polarized T H2 or T H1 cells. It has been convincingly shown that upon stimulation, T FH cells express OX14 (CD134), upregulate CD40L (CD154) and induce activation-induced cytidine deaminase expression in B cells, so that T FH cells promote germinal-center (GC) B-cell survival and differentiation, and allow immunoglobulin classswitching and somatic hypermutation. 29 They also upregulate the expression of CXCR5, the receptor for CXCL13, a chemokine produced by follicular dendritic cells (FDCs) that promotes B cell entry into the GC and therefore facilitates B-cell-T-cell contacts. T FH cells are thought to represent the malignant population in angioimmunoblastic T-cell lymphoma (AITL). 13 
Macrophages
Macrophages are part of the immune infiltrate found in a variety of lymphoma types. It has been shown in several experimental models that macrophages with STAT3 activity can negatively affect the activation of antigen-specific CD4 þ T cells. Signal transducer and activator of transcription 3, or STAT3, is a transcriptional factor activated by a number of cytokines that seem to be situated at the crossroads of multiple oncogenic signaling pathways. It is constitutively activated in tumor and immune cells of the tumor microenvironment, thus contributing to the regulation of the cell composition and role of the immune infiltrate. In fact, macrophages with STAT3 activity (STAT3 þ macrophages) are thought to play an important role in the crosstalk between tumor cells and their immunological microenvironment, leading to tumor-induced immunosuppression. Consequently, they have been proposed as being a potential target for cancer immunotherapy. 31 Similarly, macrophages with increased STAT1 activity (STAT1 þ macrophages) have been found in some lymphomas, especially surrounding tumor cells in HL and FL, where they have been associated with an unfavorable prognosis, 10 which could be associated with the immunosuppressive capacity of these macrophages.
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Dendritic cells
Recently, more attention has been paid to multiple subpopulations of dendritic cells and their role in immune surveillance. Here, we review two of these subpopulations, whose associations with lymphoma merit closer consideration.
FDCs are characterized by their ability to retain antigens for a long period, presenting intact Ag to the GC B cells (in contrast to other antigen-presenting cells that present Ag to T cells through the MHCII complex). FDCs derive from non-bonemarrow precursors and share fibroblast surface markers such as intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1, 1B10 44 and 3C8, 45 which is a novel protein with prostacyclin synthase activity that recognizes specifically FDCs and not bone-marrow-derived cells.
To mature, FDCs need to receive certain signals from the GC microenvironment where they localize, including signals from B cells. FDCs, follicular T cells and GC B cells form a network that provides B cells with survival signals, both in reactive lymphadenitis and lymphomas. The presence of FDCs in a neoplasm can be interpreted as a signal of the tumor cells' dependence on the environment, thus identifying the earlier steps of lymphomagenesis. 1 The cellular interactions between GC B cells and FDCs take place through a variety of molecules, including LFA-1/ICAM-1 and BAFF/BAFF-R. 34 Plasmacytoid dendritic cells (PDCs) make up a specialized dendritic subpopulation, with flexible functions in the immune system. They exhibit plasma cell morphology, express Toll-like receptors (TLR7, TLR8 and TLR9), BDCA-2, and BDCA4. In fact, antibodies to BDCA4 are now commonly used for magnetic bead enrichment of human PDCs in blood. After viral infection they rapidly secrete massive amounts of type I IFNs and activate NK cells, NKT cells, B cells, T cells, and myeloid dendritic cells. They then differentiate into mature dendritic cells, which are potent antigen-presenting cells that can polarize T cells. 37 A tumor counterpart of this subpopulation has been described, known as the PDC sarcoma or hematodermic CD4 þ CD56 þ neoplasm. This is a tumor that seems to exhibit distinctive homing to the skin. 46 PDCs usually occur in cutaneous lymphomas and preneoplastic inflammatory cutaneous disorders, where they play an undefined role.
Role of the microenvironment in specific lymphoma/ leukemia types
Chronic lymphocytic leukemia
An increasing number of studies show that extracellular signaling plays an important role in the development and maintenance of chronic lymphocytic leukemia (CLL). 5, 47, 48 CLL cells proliferate in anatomic structures known as proliferation centers, lacking FDCs. They are characterized by the expression of IRF4 and they provide a site for B-cell-receptor (BCR) signaling. However, the nature of the macrophages or dendritic cells that supports these proliferation centers is not well known. It is tempting to propose a relation with the nurselike cells (NLCs) described by Kipps et al. 6 NLCs are described as blood mononuclear cells that can differentiate in vitro into large, round, adherent cells that attract CLL cells and protect them from undergoing apoptosis in vitro. High levels of the TNF family members BAFF and APRIL and the chemokine CXCL12 (SDF-1), a survival factor produced by stromal cells, are expressed by NLCs. 5 Also, CD40/CD40L interactions between CLL and T-cells cooperate with BCR signaling to trigger survival of tumor B cells. 7, 49 In fact, in vitro studies have shown that soluble CD40L or autologous-activated T-cells favor the viability and proliferation of CLL B cells 50 ( Figure 1a ). Moreover, CLL cells express VEGFR1 and VEGFR2 and therefore can also profit from the growth-promoting effect of VEGF, which is produced by stromal cells or by CLL cells themselves. 51 The role of chemokines sustaining CLL cell survival.
Chemokines are a subset of cytokines that help to regulate lymphocyte trafficking, the function of the immune system, the organization of cells within the tissues and the formation of secondary lymphoid organs (for a review, see references 52 and 53 ). Lymphomas (and other cancer types) develop a complex chemokine network that determines an appropriate microenvironment for the tumor cells and allows cell growth, inhibition of apoptosis, migration and angiogenesis. CLL cells express high levels of CXCR4, the chemokine receptor for CXCL12 that directs leukemia-cell chemotaxis, and plays a critical role in CLL-cell infiltration into the bone-marrow stroma.
54 CXCL12 exerts its action by phosphorylation of the ERK1/2 mitogenactivated kinase and attracts malignant B cells to supporting microenvironments, that are otherwise restricted to hematopoietic stem cells. 5 Recently, it has been described how CXCL12 upregulates MMP-9 in B-CLL cells and promotes cell invasion and transendothelial migration. 55 This is consistent with the observation that after tissue damage and hypoxia HIF-1 induces CXCL12 expression in endothelial cells to recruit CXCR4 progenitors for tissue repair. CXCL12-CXCR4 interactions are important for the initiation and maintenance not only of CLL, but also of other hematopoietic malignancies such as FL, multiple myeloma, acute leukemia and acute myelogenous leukemia. 56 Promising results in preclinical tumor models indicate that CXCR4 antagonists may have antitumor activity in patients with various malignancies and immune diseases. 57 Indeed, one CXCR4 antagonist, AMD3100, is under evaluation in phase III clinical studies for mobilization of hematopoietic stem cells and in preclinical studies for treatment of neoplasias. Combinations of this molecule with anti-CD20 (rituximab) or anti-CD52 (alemtuzumab) antibodies might lead to an effective therapeutic alternative. However, side effects may occur in combination with chemotherapy because mobilization of progenitors (not only of malignant cells) would expose them to the cytotoxic effects of the therapy.
Other chemokine receptors, such as CCR7 (the receptor of CCL19 and CCL21 chemokines), that are expressed by CLL B cells have been shown to be important for the migration of leukemic cells into lymph nodes. 58 BAFF and APRIL contribution to survival in CLL. Increased expression of B-cell-activating factor (BAFF) and APRIL has been detected in NLCs, B-CLL cells and serum in patients. 59, 60 BAFF belongs to the tumor necrosis factor family and is also known as BLyS, zTNF4, THANK, TALL-1 and TNFSF13b. It is a critical survival factor for B cells, and is also necessary for B-cell maturation through its interaction with BAFF-R, BCMA and TACI receptors. A related molecule known as a proliferation-inducing ligand or APRIL (also named TALL-2, TRDL-1 and TNFSF13a) shares some receptors not only with BAFF, TACI and BCMA-R, but it also binds to an unidentified APRIL receptor expressed in cells lacking both TACI and BCMA (for a review about BAFF and APRIL see AlSaleem 61 ). CLL cells have been described as coexpressing BAFF-R and TACI (the latter with a variable expression pattern), leading to an autocrine activating loop. 59 However, NLC cells seem to be an important source of BAFF and APRIL (at least in the first steps of the disease) and are essential for in vitro culture of CLL cells. 5 The expression patterns of both cytokines and their receptors determine their function at every stage of B-cell maturation or in tumor pathogenesis, and defines the interactions of the B cells with their microenvironment. BAFF transgenic mice show increased numbers of mature B and T cells and an autoimmune phenotype, resembling some human autoimmune disorders, but no increase in the frequency of tumor development. 62 However, BAFF transgenic mice lacking TNF have a higher incidence of B-cell lymphomas, 63 thereby demonstrating the synergistic effect of both cytokines in tumor development. Interestingly, APRIL transgenic mice also develop lymphoid tumors that originate from expansion of the peritoneal B-1 B-cell population, resembling human CLL. 64 The mechanism by which these cytokines protect (malignant) B cells from apoptosis seems to be related to the modulation of the expression of members of the Bcl-2 family, Bcl-2 and Bcl-x L . BAFF and APRIL signaling seems not only to induce antiapoptotic proteins, but also to downregulate the proapoptotic protein Bax. 65 It has been postulated that BAFF (via BAFF-R) can activate the non-canonical nuclear factor kappa B (NFkB) pathway through the ubiquitin-mediated processing of p100 in maturing splenic B cells. This process requires p100 phosphorylation by IKKa and NFkB-inducing kinase (NIK) but not NEMO. 66 Since BAFF-R binds specifically to TNFR-associated factor (TRAF) 3 (and not to TRAF 2, 5 or 6), it has been proposed that BAFF-R could act as a repressor of TRAF3 (a negative regulator of NIK). 67 To explain how BAFF promotes cell survival, Woodland et al. 68 have proposed a model in which Akt and some of its known targets (FOXO1, FOXO3a and mTOR) become activated upon stimulation with BAFF. Pim2 has been identified as another major player in this survival signaling. Then, Akt/mTOR and Pim2 may both enhance Mcl-1 expression, which in turn triggers survival signals. Simultaneously, phosphorylation of FOXO3a by Akt leads to its cytoplasmic sequestration, removing this key transcription factor that is necessary for Bim expression (a proapoptotic protein). Relevance of BCR signaling in CLL. BCR transmits survival and death signals throughout B-cell development. Moreover, abnormal BCR stimulation provides constitutive signaling for the survival of B lymphoma cells, not only in CLL, but also in other low-grade lymphomas such as FL, mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL). 47, 69 Thus, in the characteristic CLL scenario of B-cell-T-cell contacts through CD40/CD40L, concomitant antigen stimulation can protect the malignant clone from apoptosis. In fact, a biased use of IgVH genes 70 has been demonstrated in CLL in relation to an increased usage of VH1.69. These data suggest that BCR activation presumably driven by an antigen provides key survival signals to the tumor cells. Interestingly, gene-expression profiling data show that the BCR pathway seems to be the main difference between indolent and aggressive forms of CLL. 71 Functional studies have shown that CLL cells expressing the tyrosine kinase ZAP70, which is related to a worse prognosis, have an enhanced transduction via BCR 72 and respond more rapidly to chemokine migratory signals through enhanced surface CCR7 expression. 73 
Hodgkin lymphoma
A complex network of cytokine-and cell-contact-mediated interactions between tumor and inflammatory cells is thought to regulate the proliferation of Hodgkin and Reed-Sternberg (HRS) cells. It may also rescue these cells from the proapoptotic state arising from their characteristic BCR deficiency by providing alternative survival signals. It is remarkable that HRS cells express BCMA and TACI receptors and simultaneously secrete BAFF and APRIL cytokines, which are also produced by the surrounding inflammatory cells. This creates a network of autocrine and paracrine signaling that promotes cell survival and proliferation of tumor cells. 74 HRS cells constitute a small percentage of the tumoral mass, which presents a characteristic infiltrate of inflammatory cells. T cells, which are predominantly CD4 þ , are a significant component of this HL infiltrate. These cells are not tumorantigen-specific T cells, and may be recruited non-specifically by CCL17, CCL22 and CCL11, which are produced by HL tissues.
It has been widely believed that the reactive infiltrate of HL is comprised mainly of activated Th2-like lymphocytes although these neither produce the Th2 cytokines IL-4 and IL-13 nor express functional IL-2 receptor (they can express CD25 but lack the b-chain). However, they express CTLA-4 (a costimulatory molecule expressed in Treg cells), are anergic (hyporesponsive to stimulation by mitogens and antigens) and can inhibit Th-cell responses. These data are consistent with the observation that HL-infiltrating lymphocytes are enriched in Treg cells (Figure 1d ), which create an immunosuppressive environment that explains the lack of an effective anti-tumor response to antigens expressed by HRS cells (for example, EBV proteins).
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CD8 þ cells represent a small proportion of the T-cell infiltrate and are typically not in close contact with HRS cells and, similarly to CD4 T cells, do not seem to be directed against a common antigen. Although the amount of CD8 þ is higher in EBV þ cases, and EBV-specific cytotoxic T lymphocytes (CTLs) can be detected in the peripheral blood of patients with EBV þ classic HL, no CTLs targeting EBV proteins expressed by HRS cells can be identified within the tumors. Moreover, the presence of a high percentage of activated CTLs (granzyme B þ ) in the affected tissue is a marker of unfavorable prognosis associated with shorter progression-free survival. 10, 76 These findings suggest that CTLs that potentially target the HRS cells either fail to penetrate the tumor site or fail to function within the tumor microenvironment. This could be the final consequence of changes in the HL cells, such as downregulation of MHC-I in HRS cells, 77 or induction of local T-cell anergy by IL10, TGF-b, expression of perforin-neutralizing proteins and induction of apoptosis in CTLs by HRS cells via CD95L.
Some findings regarding the function of macrophages and different T-cell subsets are proving to be of interest. For instance, the composition of the T-cell infiltrate (CTLs vs Treg cells) has been found to be a predictive factor of clinical outcome in HL. A small number of FOXP3 þ (Treg) cells and a high degree of infiltration of TIA-1 þ cells (CTLs, NK, neutrophils and macrophages) represent an independent prognostic factor of unfavorable outcome (event-free and disease-free survivals). 9 Another interesting observation is the presence of STAT1-activated macrophages surrounding HL cells, associated with unfavorable prognosis, 10 which could be associated with the immunosuppressive capacity of STAT1-activated macrophages 32 ( Figure 1b) . It is also important to consider cell-contact interactions between T cells and HRS through a variety of surface molecules expressed by HRS, such as CD40L (for CD40), CD27 (for CD70), CD4 (for HLA-II), CD28/CTLA4 (for CD80/86) and LFA-1 (for ICAM-1; binding to lymphocytes in an antigen-independent manner), 78 which underlines the presence of crosstalk between HL and T cells.
Lymph nodes involved in cHL are typically heavily infiltrated by eosinophils (Figure 1b ). Cytokines and chemokines may contribute to this eosinophilia by increasing the production/ activation of eosinophils and stimulating their recruitment to the site of cHL involvement (via IL5, CCL28 and CCL11 secreted by HRS cells themselves or by fibroblasts and macrophages). Eosinophils express ligands for CD30 and CD40 (receptors expressed by HRS), providing proliferative and antiapoptotic signals for HRS cells. Furthermore, eosinophils produce TGF-b and may therefore be involved in fibroblast activation and fibrosis. A high eosinophil content was found to be related to poor prognosis, 11 although this has not been confirmed by other studies. 79 Many fibroblast-like cells can be detected, often in association with HRS cells, especially in the nodular sclerosis subtype. Three crucial mechanisms have been proposed as being involved in the generation of fibrosis: (1) unbalanced production of Th2 over Th1 cytokines causes an abnormal reaction to tissue damage (for example, fibroblasts express IL-13R, especially in the nodular sclerosis subtype, and can be activated by IL-13 secreted by HRS cells); (2) the increased production of TGF-b and b-FGF by HRS and reactive cells (potent stimulators of fibroblast proliferation and ECM protein synthesis); (3) the engagement of CD40, expressed by fibroblasts, by CD40L (expressed by activated T cells, mast cells and eosinophils). Primary fibroblasts from HL also produce growth factors for HRS cells, such as IL6 and IL7. 80, 81 CD30 role in Hodgkin lymphoma. CD30 (TNFRSF8) expression is a feature of malignant cells in HL and anaplastic large cell lymphoma, although it can also be seen in other neoplastic and activated lymphocytes. 82 The corresponding ligand (CD30L, also known as CD153) is a type II transmembrane glycoprotein of the TNF superfamily. CD30L is expressed by bystander cells such as T cells, macrophages, eosinophils and predominantly mast cells that can be found within the massive inflammatory infiltrate in HL. 83 CD30 signaling is mediated by interactions with TRAF1, 2 and 5, which in turn lead to NFkB activation. [84] [85] [86] [87] [88] Recruitment of TRAF proteins to the cytoplasmic tail of the receptor transduces signals to activate IKK, which phosphorylates IkBa and triggers NFkB translocation into the nucleus. 89 New data, which require confirmation, suggest that CD30 can trigger upregulation of CXCR4 in non-Hodgkin lymphoma (NHL) cell lines, T lymphocytes, and in one HL cell line, 90, 91 providing a new link between CD30-expressing lymphomas and their microenvironment.
On the other hand, recent reports show that CD30L-reverse signaling is also feasible, since the structure of CD30L (with a C-terminal extracellular domain and a short intracellular N-terminal domain) allows the ligand to act as a receptor that can transmit downstream signals. In that case, CD30/CD30L interactions lead to increased expression and segregation of some chemokines (IL-8, MIP-1a and MIP-1b) in mast cells, that are capable of recruiting most of the cell types found in the HL microenvironment or in the inflammatory infiltrate of other diseases. 92 Although the relevance of CD30 signaling in HL has been well demonstrated, it remains controversial whether CD30 activation comes from CD30L stimulation by mast cells and other cells within the inflammatory infiltrate, has an autocrine regulation, or is ligand-independent.
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Role of EBV in Hodgkin lymphoma. Several lymphomas have been consistently associated with Epstein-Barr virus, including Burkitt lymphoma and HL. In the latter, HRS cells are derived from GC B cells that have lost the expression of BCR but have escaped apoptosis. A highly interesting observation by Kuppers and coworkers 94 is that EBV plays a central role in the pathogenesis of classic HL (and also in other diseases such as post-transplant lymphoproliferative disorders) by rescuing BCRdeficient, preapoptotic GC B cells from apoptosis. Thus, EBV infection renders the HRS cells independent of survival signals normally supplied by the BCR. Therefore, it has been proposed that LMP1 and LMP2A EBV proteins, mimicking CD40 and BCR, respectively, could provide the necessary survival signals to the malignant cells. 95 
Angioimmunoblastic T-cell lymphoma
Recent data from a series of AITL cases support the idea that T FH cells are the normal counterpart of tumor cells in this malignancy. These findings indicate a gene-expression profile defined by a strong microenvironment signature (including overexpression of genes from B cells, FDCs, genes related to the extracellular matrix, vascular biology and chemokines) and a signature that corresponds to normal T FH cells (CXCL13, BCL6, PDCD1, CD40L and NFAT) and is enriched after T FH cell sorting. 13 Histologically AITL is a neoplasm of T FH cells 29, 96 associated with an expansion of FDC networks containing neoplastic T cells and scattered EBV þ B immunoblasts (Figure 1c) . EBV infection is probably the result of the immunodysregulation characteristic of this malignancy that leads to the loss of immune surveillance. Early lymph-node involvement by AITL is characterized by a selective GC pattern, while advanced AITL may have a diffuse pattern. This probably reflects the existence of additional cytogenetic or molecular alterations that confer a survival advantage on the tumor cells. The nature of the numerous B cells that can be found in AITL has been controversial. Indeed, progression to bona fide B-cell lymphoma is an exceptional finding in AITL cases displaying monoclonal immunoglobulin (Ig) rearrangements, implying that this is a virally induced reversible lymphoproliferative process, dependent on the continued survival stimulus received from the neoplastic T FH cells. Moreover, AITL tumor cells 96 depend on chemokine signaling mediated by CXCL13 for appropriate homing and proliferation.
This phenomenon is the opposite of that observed in the T-cell-rich B-cell lymphoma, an aggressive B-cell lymphoma in which a minority of GC-derived neoplastic B cells persist within a background of reactive T cells and histiocytes. 20 Interestingly, the phenotype of these T cells does not correspond to follicular T cells, and they seem to consist mainly of cytotoxic T cells. 21 
Follicular lymphoma
FL cells grow surrounded by the same cell compartments as normal follicles, including helper T cells, FDCs and macrophages. This suggests that the survival of the tumor cells may depend on their interaction with the stroma (Figure 1d ). The tumor cells may eventually grow in a diffuse pattern, with a higher growth fraction, but only after acquiring p53 mutation or other additional genetic changes.
The dependency of FL cells on their microenvironment is supported by the fact that these cells are very difficult to grow in vitro in the absence of stromal cells and without stimulation of the CD40 receptor, which is a major signaling pathway for interactions between B and T cells 15 ( Figure 1d ). Moreover, Irish et al. 97 have demonstrated that BCR-mediated signaling via phosphorylation of Syk, Btk, Erk1/2 and p38 occurs more rapidly in tumor B cells from FL samples than in infiltrating non-tumor B cells, and achieves stronger and more sustained signaling. Using gene-expression profiling, Dave et al. 98 identified two signatures that together represented the best predictor of survival for FL patients. This model divides the patient into quartiles based on survival time. The genes that best defined both signatures were expressed primarily by T cells, macrophages or dendritic cells, but not by the tumor cells themselves. A subsequent study by Alvaro et al. 33 confirmed that lymphoma-associated macrophages are an independent predictor of survival. 16 They also showed that the presence of STAT1 þ macrophages is an important independent prognostic factor for shorter overall survival in FL, independent of the International Prognostic Index classification. All these results imply the participation of immune cells in the biology and pathogenesis of this type of tumor.
More recently, an immunohistochemistry study in a large series of FL cases confirmed the value of a specific subset of T cells, Treg cells, as a predictor factor. Additionally, in this study the authors demonstrated that a small number of Treg cells is associated with transformation to DLBCL.
14 Furthermore, FL Treg cells from FL samples have been shown to suppress CD4 and CD8 T cell function and cytokine production after CD3/ CD28 stimulation, whereas this suppressor activity was not apparent in Treg cells from normal or reactive nodes. This activity appears to be mediated through TGF-b, whose inhibition may have therapeutic benefits for patients. 17 FL is also characterized by an increased expression of specific chemokines. Thus, it has been shown that chemokines CXCL12 and CXCL13 enhance the migration of follicular center lymphoma B cells.
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Diffuse large B-cell lymphoma DLBCL, the most common subtype of NHL, is the paradigm of clinical and biological heterogeneity. Although part of this heterogeneity is attributable to the tumor cells themselves, a significant fraction depends on the microenvironment. Two recent studies have identified some key components of this environment. Thus, Shipp et al. 18, 101 established three robust DLBCL subsets including the OxPhos cluster, the BCR/proliferation cluster, and the host response (HR) cluster. Interestingly, the BCR/proliferation cluster displays strong expression of cell-cycle regulatory genes, B-cell-specific transcription factors and components of the BCR, such as CD79a, CD19, BLK, SYK and PLCG2. Immunohistochemistry studies with 200 de novo DLBCL cases have confirmed the relevance of BCR signaling in DLBCL, and have identified that the expression of PKCb (a protein kinase involved in BCR signaling) or cyclin D2 is an independent predictor of poor overall survival. 102 HR-cluster tumors are defined by the presence of an inflammatory infiltrate characterized by T/NK and interdigitating dendritic cells that could be directed against the same antigen as tumor B cells, and would therefore support their growth. On the other hand, it is also possible that the infiltrating T cells are directed against the malignant B cells. Nevertheless, the HR signature was not associated with a better prognosis, probably due to an ineffective immune response. The subtypes defined by Shipp et al. do not correlate well with those identified as 'cell of origin' subgroups. 103, 104 Nevertheless, the analysis of the data generated by Staudt et al. has identified a lymph-node signature 19 that includes many genes whose expression patterns are associated with favorable survival in DLBCL 105 and reflect a HR to malignant DLBCL cells in the lymph node. This lymph-node signature includes genes expressed in macrophages and fibroblasts, and genes that encode extracellular matrix components, 105 and therefore, it is essentially attributable to the nonmalignant cells. Moreover, the intensity of expression of the lymph-node signature was associated with low tumor stage and was inferior in the ABC-DLBCL cases with a more aggressive behavior. 19 A peculiar subtype of DLBCL, the primary mediastinal type (PMBCL), deserves special attention. These tumors show low levels of expression of multiple components of the BCR signaling cascade including the cell-surface immunoglobulin receptor, IgM, the Iga/b-associated SRC family protein tyrosine kinase PTK, BLK, BLNK, SAB, PLCG2 and PKCb. However, PMBCL tumors express NFkB target genes and present nuclear NFkB subunit translocation, suggesting that NFkB is constitutively activated and can release tumor cells from their BCRmediated survival dependency. 106 This resembles the situation in HL, where NFkB activation is independent of BCR signaling, since HRS cells do not express BCR genes.
Splenic marginal zone lymphoma
Although a relatively infrequent tumor, splenic marginal zone lymphoma (SMZL) strongly supports the role of the antigen selection in B-cell lymphomas. Thus, both a highly biased use of IgVH genes, with increased usage of VH1.2 genes, antigendriven, BCR stimulation provides tumor cells with key survival signaling. 22, 70, 107 Additionally, an intriguing association has been recently established between hepatitis C virus (HCV) infection and SMZL, which supports the hypothesis that the stimulation of marginal zone B cells in the spleen by persistent HCV antigens, particularly the E2 viral antigen, is involved in the pathogenesis of SMZL. Thus, hepatitis C infection was reported in 10-16% of SMZL patients 108 and up to 50% in splenic DLBCL. 109 Moreover, regression of SMZL has been described in patients with HCV after antiviral treatment, thereby demonstrating a direct involvement of HCV in lymphomagenesis. 3 Interestingly, symptomatic mixed cryoglobulinemia was a common feature in these cases. 108 Nevertheless, the presence of HCV in lymphoid neoplasms seems to be characteristic of specific geographic areas, such as Italy and Japan, and to be restricted to some tumor types, in particular SMZL, other marginal zone lymphomas and lymphoplasmacytic lymphomas. 110, 111 Another striking example of an association between infection and lymphomagenesis is a disorder with features of SMZL, characterized by splenomegaly and circulating naïve CD5-negative villous B lymphocytes that is known to be associated with malaria and idiopathic splenomegaly. [23] [24] [25] [26] MALT-type marginal zone lymphoma A highly instructive illustration of the dependence of tumor-cell survival on the presence of microbial or viral pathogens has been provided by observations of mucosa-associated lymphoid tissue-type (MALT type) gastric MZL and the bacterium Helicobacter pylori.
2 Several lines of evidence support the hypothesis that H. pylori can provide the antigenic stimulus to promote and sustain the growth of MALT-type marginal zone B cells in the stomach, first causing acute and chronic gastritis, and subsequently gastric lymphoma 112 (for a recent review, see Sagaert et al.
4
). An increasing number of reports claim a role for various bacterial infections in the development of some minority types of lymphoma, such as Borrelia and skin marginal zone lymphoma 113 and Chlamydia psittaci and ocular adnexal MALT lymphoma. 114, 115 Lecuit et al. 116 recently reported that the analysis of intestinal tissue obtained from a patient with immunoproliferative small intestinal disease who had a dramatic response to antibiotics revealed the presence of Campylobacter jejuni. They also showed that the analysis of archival specimens disclosed Campylobacter species in four out of six additional patients with the same condition. This and similar findings relating Borrelia and cutaneous marginal zone lymphoma would require experimental demonstration in order to confirm that the proliferation of the neoplastic cells is dependent on the presence of the specific pathogens, and to clarify the role of accompanying T cells.
Concluding comments
Survival of the tumor cells in a wide range of lymphoma types is dependent on the signals derived from B-and T-cell receptors and that provided by TNF-receptor family members. The analysis of the interactions between tumor and microenvironment could provide a basis for the development of alternative treatments aimed at interfering with the survival signaling derived from antigens and inflammatory cells.
